peer reviewedParkinson’s disease (PD) is the second most prevalent neurodegenerative disease, with an increasing incidence in recent years due to the ageing population. Genetic mutations alone only explain <10% of PD cases, while environmental factors, including small molecules, may play a significant role in PD. In the present work, 22 plasma (11 PD, 11 control) and 19 feces samples (10 PD, 9 control) were analyzed by non-target high resolution mass spectrometry (NT-HRMS) coupled to two liquid chromatography (LC) methods (reversed phase (RP) and hydrophilic interaction liquid chromatography (HILIC)). A cheminformatics workflow was optimized using open software (MS-DIAL and patRoon) and open databases (all public MSP-formatted spectral libr...
Progression of Parkinson’s disease (PD) is highly variable, indicating that differences between slow...
Characterisation and diagnosis of idiopathic Parkinson's disease (iPD) is a current challenge that h...
BACKGROUND: Reliable and sensitive biomarkers are needed for enhancing and predicting Parkinson\u27s...
peer reviewedParkinson’s disease (PD) is the second most prevalent neurodegenerative disease, with a...
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease, with an increasing ...
Abstract Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease of the cent...
Parkinson ’ s disease (PD) is a multifactorial neurodegenerative disorder in which environmental (li...
Introduction: About 90% of cases of Parkinson’s disease (PD) are idiopathic and attempts to understa...
The plasma of Parkinson's disease (PD) patients may contain various altered metabolites associated ...
Biomarker research in Parkinson’s disease (PD) has long been dominated by measuring dopamine metabol...
<p>Parkinson's disease (PD) shows high heterogeneity with regard to the underlying molecular pathoge...
<p>Parkinson's disease (PD) shows high heterogeneity with regard to the underlying molecular pathoge...
Parkinson’s disease (PD) shows high heterogeneity with regard to the underlying molecular pathogenes...
OBJECTIVE: To determine whether a Parkinson disease (PD)-specific biochemical signature might be fou...
Progression of Parkinson's disease (PD) is highly variable, indicating that differences between slow...
Progression of Parkinson’s disease (PD) is highly variable, indicating that differences between slow...
Characterisation and diagnosis of idiopathic Parkinson's disease (iPD) is a current challenge that h...
BACKGROUND: Reliable and sensitive biomarkers are needed for enhancing and predicting Parkinson\u27s...
peer reviewedParkinson’s disease (PD) is the second most prevalent neurodegenerative disease, with a...
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease, with an increasing ...
Abstract Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease of the cent...
Parkinson ’ s disease (PD) is a multifactorial neurodegenerative disorder in which environmental (li...
Introduction: About 90% of cases of Parkinson’s disease (PD) are idiopathic and attempts to understa...
The plasma of Parkinson's disease (PD) patients may contain various altered metabolites associated ...
Biomarker research in Parkinson’s disease (PD) has long been dominated by measuring dopamine metabol...
<p>Parkinson's disease (PD) shows high heterogeneity with regard to the underlying molecular pathoge...
<p>Parkinson's disease (PD) shows high heterogeneity with regard to the underlying molecular pathoge...
Parkinson’s disease (PD) shows high heterogeneity with regard to the underlying molecular pathogenes...
OBJECTIVE: To determine whether a Parkinson disease (PD)-specific biochemical signature might be fou...
Progression of Parkinson's disease (PD) is highly variable, indicating that differences between slow...
Progression of Parkinson’s disease (PD) is highly variable, indicating that differences between slow...
Characterisation and diagnosis of idiopathic Parkinson's disease (iPD) is a current challenge that h...
BACKGROUND: Reliable and sensitive biomarkers are needed for enhancing and predicting Parkinson\u27s...